 Artist: Fairyland: mp3 download Genre(s): Metal: Power Fairyland's discography:  Of Wars In Osyrhia Year: 2003 Tracks: 11  Of Wars In Osyrhia Year: 2003 Tracks: 3 Clearly candidates for the "most un-metallic heavy metallic element band identify always conceived" competition, France's Fairyland particularize in larger-than-life, fantasy-laced, keyboard-driven, Italy's Rhapsody and Germany's Avantasia, among others. First conceived of in 1998 by multi-instrumentalist Willdric Lievin, Fairyland step by step accumulated collaborators Anthony Parker (guitar) and Philippe Giordana (keyboards) in the side by side few years, merely only got around to transcription their debut disc album, Of Wars in Osyrhia, in 2003 -- when they attained the services of Spanish singer Elisa C. Martin, then currently in transition between her early band Dark Moor and her side by side project, Dreamker. Fairyland have yet to record once more since her loss. |
Wednesday, 20 August 2008
Mp3 music: Fairyland
Sunday, 10 August 2008
Renal Cell Carcinoma
�UroToday.com - Metastatic nephritic cell carcinoma was once considered to be a disease without significant therapeutic leads. Intravenous administration of interleukin-2 was until latterly the solely FDA approved treatment for metastatic nephritic cell carcinoma. Interleukin-2 at best results in lasting complete responses in less than 10% of patients.
Considerable toxicity is encountered with this regimen, including fluid keeping, renal inadequacy, and hypotension. An alternate standard of care, subcutaneously administered interferon-alpha, produces fewer durable responses with slope effects including fatigue, low, and cytopenia. There was clearly an unmet medical need for more in force and less toxic treatments for metastatic renal cellular telephone carcinoma.
A better apprehension of the molecular changes responsible for the development of nephritic cell carcinoma has lede to a new therapeutic target: angiogenesis. The identification of the deletion or silencing of the Von Hippel Landau protein in and its role in the ascendence of angiogenesis through HIF (Hypoxia Inducible Factor has led to clinical trials which value drugs targeted to this pathway.
There are 3 ligands and receptors of the VEGF class, homo and heterodimerization can lead to different biological personal effects including hemangiogenesis, angiogenesis, and lymphangiogenesis. Of the 3 ligands in the VEGF class, the one most important to cancer prison cell angiogenesis is VEGF A. This ligand binds to the VEGF-2 receptor. There are multiple ways in which this target commode be inhibited. Antibodies can prevent the binding of the VEGF-A ligand to the sense organ. Drugs which work by this mechanism include bevacuzimab. The signal cascade of the VEGF a receptor can be blocked by tyrosine kinase inhibitors. Two drugs in this class include sorafanib and sunitinib.
Motzer et al evaluated the multitargeted receptor kinase receptor inhibitor sunitinib in patients with metastatic pass cell carcinoma. Both sunitinib targets the kinase activity of the both vascular endothelial emergence factor receptor B and platelet derived growth factor A add up of 750 patients were randomized to receive sunitinib 50 mg orally daily for 4 weeks with a 2 week break, or interferon, starting at 3 MU TIW.
The primary termination of his study was progression free survival, with secondary endpoints including overall survival reply rate and toxicity.. Stratification factors included serum LDH, ECOG performance status, as well as presence or absence of a nephrectomy. The majority of the patients entered in this study were good to intermediate risk of exposure. When evaluated by a central recapitulation, 31% of patients toughened with sunitinib and 6% of patients treated with interferon demonstrated a reaction.
The medial progression free survival utilizing the results from this independent reassessment was 11 months vs 5 months. This handling effect was observed for all MSKCC risk factors including prior nephrectomy, ECOG performance position, LDH, haemoglobin and corrected calcium. Significant differences in toxicities included neutropenia (11/1) and lymphocytopenia in the interferon arm. Fatigue was also greater in the interferon arm. Grade 3 or 4 diarrhea (5%), hypertension (8%), and hand-foot syndrome (5%) were at a significantly higher charge per unit in the sunitinib weapon than the interferon weapon. Using the functional assessment of cancer therapy-general (FACT-G) score, character of life parameters were also significantly better in the sunitinib arm compared to the interferon arm.
The average overall survival has yet to be reached for both groups. An update of this data presented at ASCO 2008 demonstrated a superior survival for sunitinib when compared to interferon alpha.
The PTEN/AKT pathway controls a variety of cellular functions, including angiogenesis, cell proliferation, gluconeogesis and apoptosis. One of the downstream elements of PTEN pathway is mTOR which acts as a detector for metabolism. mTOR tin control protein synthesis, be considered as a maestro switch for metabolism, proteins involved in transcription, translation and cell cycle control. Hudes et al studied CCI 779, an inhibitor of the final common pathway of ATK, mTor, in a 3 armed randomized test where this drug was compared to interferon or the compounding of CCI 779 and interferon. In contrast to the Motzer study, where patients were predominately good or intermediate risk, patients were requisite at ledger entry to hold 3 or more poor risk features as outlined by the Motzer criteria. Patients standard interferon 3 times per week, escalating to a total dose of 18 MU. TEMS 25 mg IV weekly, and Temsr combined with interferon at 6 MU. As expected the primary side effect of interferon was asthenia, with 27% of patients demonstrating form 3 or 4 toxicity. The overall improvement in median survival of the single agent was 3.6 months, an an improved time to progression 1.8 months. Other mTOR inhibitors demonstrated call in metastatic renal cell carcinoma. RAD001 demonstrated an improved survival compared to best supportive care in patients wHO failed a previous tyrosine kinase inhibitor.
Presented by: Daniel P. Petrylak, MD, at the Masters in Urology Meeting - July 31, 2008 - August 2, 2008, Elbow Beach Resort, Bermuda
UroToday - the only urogenital medicine website with original cognitive content written by global urology key view leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
www.urotoday.com
Copyright � 2008 - UroToday
More info
Considerable toxicity is encountered with this regimen, including fluid keeping, renal inadequacy, and hypotension. An alternate standard of care, subcutaneously administered interferon-alpha, produces fewer durable responses with slope effects including fatigue, low, and cytopenia. There was clearly an unmet medical need for more in force and less toxic treatments for metastatic renal cellular telephone carcinoma.
A better apprehension of the molecular changes responsible for the development of nephritic cell carcinoma has lede to a new therapeutic target: angiogenesis. The identification of the deletion or silencing of the Von Hippel Landau protein in and its role in the ascendence of angiogenesis through HIF (Hypoxia Inducible Factor has led to clinical trials which value drugs targeted to this pathway.
There are 3 ligands and receptors of the VEGF class, homo and heterodimerization can lead to different biological personal effects including hemangiogenesis, angiogenesis, and lymphangiogenesis. Of the 3 ligands in the VEGF class, the one most important to cancer prison cell angiogenesis is VEGF A. This ligand binds to the VEGF-2 receptor. There are multiple ways in which this target commode be inhibited. Antibodies can prevent the binding of the VEGF-A ligand to the sense organ. Drugs which work by this mechanism include bevacuzimab. The signal cascade of the VEGF a receptor can be blocked by tyrosine kinase inhibitors. Two drugs in this class include sorafanib and sunitinib.
Motzer et al evaluated the multitargeted receptor kinase receptor inhibitor sunitinib in patients with metastatic pass cell carcinoma. Both sunitinib targets the kinase activity of the both vascular endothelial emergence factor receptor B and platelet derived growth factor A add up of 750 patients were randomized to receive sunitinib 50 mg orally daily for 4 weeks with a 2 week break, or interferon, starting at 3 MU TIW.
The primary termination of his study was progression free survival, with secondary endpoints including overall survival reply rate and toxicity.. Stratification factors included serum LDH, ECOG performance status, as well as presence or absence of a nephrectomy. The majority of the patients entered in this study were good to intermediate risk of exposure. When evaluated by a central recapitulation, 31% of patients toughened with sunitinib and 6% of patients treated with interferon demonstrated a reaction.
The medial progression free survival utilizing the results from this independent reassessment was 11 months vs 5 months. This handling effect was observed for all MSKCC risk factors including prior nephrectomy, ECOG performance position, LDH, haemoglobin and corrected calcium. Significant differences in toxicities included neutropenia (11/1) and lymphocytopenia in the interferon arm. Fatigue was also greater in the interferon arm. Grade 3 or 4 diarrhea (5%), hypertension (8%), and hand-foot syndrome (5%) were at a significantly higher charge per unit in the sunitinib weapon than the interferon weapon. Using the functional assessment of cancer therapy-general (FACT-G) score, character of life parameters were also significantly better in the sunitinib arm compared to the interferon arm.
The average overall survival has yet to be reached for both groups. An update of this data presented at ASCO 2008 demonstrated a superior survival for sunitinib when compared to interferon alpha.
The PTEN/AKT pathway controls a variety of cellular functions, including angiogenesis, cell proliferation, gluconeogesis and apoptosis. One of the downstream elements of PTEN pathway is mTOR which acts as a detector for metabolism. mTOR tin control protein synthesis, be considered as a maestro switch for metabolism, proteins involved in transcription, translation and cell cycle control. Hudes et al studied CCI 779, an inhibitor of the final common pathway of ATK, mTor, in a 3 armed randomized test where this drug was compared to interferon or the compounding of CCI 779 and interferon. In contrast to the Motzer study, where patients were predominately good or intermediate risk, patients were requisite at ledger entry to hold 3 or more poor risk features as outlined by the Motzer criteria. Patients standard interferon 3 times per week, escalating to a total dose of 18 MU. TEMS 25 mg IV weekly, and Temsr combined with interferon at 6 MU. As expected the primary side effect of interferon was asthenia, with 27% of patients demonstrating form 3 or 4 toxicity. The overall improvement in median survival of the single agent was 3.6 months, an an improved time to progression 1.8 months. Other mTOR inhibitors demonstrated call in metastatic renal cell carcinoma. RAD001 demonstrated an improved survival compared to best supportive care in patients wHO failed a previous tyrosine kinase inhibitor.
Presented by: Daniel P. Petrylak, MD, at the Masters in Urology Meeting - July 31, 2008 - August 2, 2008, Elbow Beach Resort, Bermuda
UroToday - the only urogenital medicine website with original cognitive content written by global urology key view leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
www.urotoday.com
Copyright � 2008 - UroToday
More info
Subscribe to:
Posts (Atom)